Skip to main content
Equibles

Balyasny Asset Management L.P.

Position in RARE — Ultragenyx Pharmaceutical Inc.

CIK 1218710 Chicago, IL
Back to RARE Full portfolio

Position in RARE

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$8,052,425
-$3,908,817 QoQ
Shares Held
384,364
-26.1% QoQ
Ownership
0.390%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2020
13 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in RARE Over Time

Shares Held

Position Value (USD)

Derivatives in RARE

reported options exposure · as of Dec 31, 2025
CallValue
$4,188,300
CallShares
182,100
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Balyasny Asset Management L.P. holds $2,351,657,469 across 178 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 APGE
Apogee Therapeutics, Inc.
 1,665,102 $221,008,988
2 INSM
INSMED Inc
 1,326,430 $141,423,966
3 BBIO
BridgeBio Pharma, Inc.
 1,230,052 $91,614,272
4 ABVX
Abivax S.A.
 603,840 $80,467,718
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 145,005 $72,028,333
6 TNGX
Tango Therapeutics, Inc.
 2,016,379 $63,032,007
7 CYTK
Cytokinetics Inc
 711,676 $60,627,678
8 BMRN
Biomarin Pharmaceutical Inc
 1,054,613 $60,344,955

All Filings in RARE

Export CSV
17 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $8,052,425 384,364
2025-12-31 $11,961,242 520,054
2025-12-31 $4,188,300 182,100
2025-09-30 $9,324,800 310,000
2025-06-30 $2,563,198 70,495
2025-06-30 $6,726,600 185,000
2025-03-31 $12,673,500 350,000
2025-03-31 $4,083,220 112,765
2024-12-31 $4,207,000 100,000
2024-12-31 $4,623,493 109,900
2024-03-31 $1,342,010 28,743
2023-12-31 $3,965,856 82,933
2022-12-31 $56,476 1,219
2022-09-30 $414,100 10,000
2021-09-30 $320,445 3,553
2021-03-31 $525,122 4,612
2020-12-31 $1,281,584 9,258